Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
$74.12
$4.44(4.82%)
At close: 4:00 PM EST
$74.12
$4.44(4.82%)
Day’s Range― - ―
52-Week Range$74.08 - $109.50
Previous CloseN/A
Volume5.49M
Average Volume (3M)15.44M
Market Cap
$110.11B
Enterprise Value$120.26B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$12.05B
Price to Earnings (P/E)38.2
Beta0.86
Next Earnings
Apr 29, 2026EPS Estimate
0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding1,483,019,800
10 Day Avg. Volume25,980,856
30 Day Avg. Volume15,436,054
Financial Highlights & Ratios
PEG Ratio4.27
Price to Book (P/B)6.04
Price to Sales (P/S)7.85
P/FCF Ratio49.69
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.22
Enterprise Value/Gross Profit9.55
Enterprise Value/Ebitda23.94
Forecast
1Y Price Target
$108.14Price Target Upside45.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)3.46
Revenue Forecast (FY)$22.28B
Bulls Say, Bears Say
Bulls Say
Champion Clinical TrialUsing the same clinical endpoints as a previously successful study increases the likelihood that the Champion trial will show favorable results and could materially expand the pool of patients eligible for the Watchman device, creating upside not reflected in current sales estimates.
Valuation And Analyst ConvictionAnalyst Buy ratings and the view that the stock is undervalued relative to its growth drivers create a constructive setup for further upside if execution and clinical readouts meet expectations.
Vascular Therapies Product LaunchA new intravascular lithotripsy product combined with improving reimbursement dynamics should support revenue growth and a healthier product mix in the vascular therapies franchise.
Bears Say
Delayed Commercial Impact From ChampionCompany cautions that commercial benefits from Champion may be delayed after a successful trial, which could limit the speed at which favorable clinical results translate into revenue gains.
Electrophysiology Demand HeadwindsUnexpected slowdowns in U.S. and global electrophysiology revenue, product discontinuations, and reduced offerings have prompted analysts to lower revenue forecasts and could weigh on organic growth.
Investor Positioning And Reduced DemandCrowded long positioning among institutional investors and reluctance from many long-only managers to add exposure ahead of a pivotal trial outcome have amplified selling pressure and reduced natural buyers for the shares.
Boston Scientific News
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $74.08 and its highest was $109.50 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $110.11B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Apr 29, 2026 which is in 76 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Feb 04, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.781 by $0.019.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.79.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,483,019,800 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.8 in its last earnings report, beating expectations of $0.781. Following the earnings report the stock price went down -17.594%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Company Deck
BSX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized materially strong financial performance in 2025 (record revenues >$20B, double-digit organic growth, EPS and margin expansion, and robust free cash flow) with multiple high-growth franchises (EP, WATCHMAN, IO, cardiovascular) and confident 2026 guidance and long-range targets. Challenges were acknowledged — AXIOS product removal affecting Endo H1, ACURATE discontinuation impacting EMEA and Q1, underperformance in urology, a meaningful GAAP litigation charge, and competitive share dynamics in EP — but management provided mitigation paths and timing for resolution (midyear fixes, product launches, tuck-in M&A). Overall, positives (broad-based growth, margin and cash-flow improvement, strong clinical catalysts and strategic deals) significantly outweigh the manageable operational and one-time headwinds.View all BSX earnings summariesBSX Revenue Breakdown
35.79% MedSurg
64.22% Cardiovascular
BSX Stock 12 Month Forecast
Average Price Target
$108.14
▲(45.89% Upside)
Technical Analysis
Abbott Laboratories
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.16% Insiders
26.55% Mutual Funds
6.48% Other Institutional Investors
44.09% Public Companies and Individual Investors